Ask AI
EGFRm NSCLC Strategies

CE / CME

Personalizing EGFR Mutation–Positive NSCLC Care: Strategies for the Advanced Practice Provider

Nurse Practitioners/Nurses: 0.50 Nursing contact hours, includes 0.50 hour of pharmacotherapy credit

Physician Assistants/Physician Associates: 0.50 AAPA Category 1 CME credit

Released: June 23, 2026

Expiration: December 22, 2026

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

How many people with lung cancer do you provide care for in a typical month?

2.

For those who practice in academic or community settings, please indicate your practice setting:

3.

Your patient is a 55-year-old woman newly diagnosed with stage IV EGFR-mutated NSCLC (L858R). During her consultation to discuss therapy options, she says that she would prefer to avoid chemotherapy and would like to better understand her other treatment options. 

What would you tell her regarding the expected improvement in median overall survival outcomes with amivantamab plus lazertinib compared with osimertinib monotherapy as reported from the MARIPOSA phase III trial?

4.

What duration of prophylactic anticoagulants is recommended for patients with advanced EGFR-mutated NSCLC who are starting therapy with amivantamab plus lazertinib?